CTIS2023-508432-53-00
Recruiting
Phase 1
SUBCUTANEOUS INJECTIONS OF CULTURED ADIPOSE-DERIVED STROMA/ STEM CELLS TO HEAL REFRACTORY ISCHEMIC DIGITAL ULCERS IN PATIENTS WITH SCLERODERMA:A PHASE II STUDY - RC31/17/0447
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Systemic sclerosis
- Sponsor
- Centre Hospitalier Universitaire De Toulouse
- Enrollment
- 32
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Over 18 years old systemic sclerosis according to the 2013 ACR/EULAR classification criteria,, at least one digital ulcer at baseline showing all the following characteristics: a) located beyond the proximal interphalangeal joint, on finger surface (included periungueal ulcers), b) of ischemic origin according to the physician, c) not over subcutaneous calcifications or bone relief, d) active DU, e) refractory after 10±2 weeks of standard of care (that is either still active or new occurrence despite standard of care)\- Patient must have provided written informed consent prior to enrolment,, Patient must be able to understand their requirements of participating in the protocol,, Patient affiliated to a social security system.
Exclusion Criteria
- •Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,, Patient who underwent autologous hematopoietic stem cell transplantation (HSCT) within less than 1 year,, Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines),, History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study,, Subjects who have active proliferative retinopathy,, Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months, Patient who had severe cardiac failure in the last 6 months, Females who are pregnant or breastfeeding or plan to do so during the course of this study,, Patient under judicial protection or unable to express consent, Vulnerable patient (pregnancy or lactating women, parturients, persons deprived of their liberty by judicial or administrative decision, persons undergoing psychiatric treatment, persons admitted to a health or social establishment for purposes other than research, Refusal of the patient to participate in the study., Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,, Digital ulcer due to conditions other than scleroderma, Non ischemic digital ulcer,, Ulcers with osteomyelitis, or clinically uncontrolled infection,, Infected digital ulcer requiring systemic antibiotherapy,, Digital ulcer requiring urgent surgery., Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,, Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to inclusion visit”,, Use of topical growth factors, hyperbaric oxygen,, Local injection of botulinum toxin in an affected finger within 4 weeks prior to inclusion visit”,, Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, within one month prior injection, Treatment with oral corticosteroids (\> 10 mg/day of prednisone or equivalent),, Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to inclusion visit”,
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Adipose tissu derived-stem cells injections from patients with sclerodermia to treat thier refractory digital ulcers.Patients with systemic sclerosis presenting digital ulcer :- located beyond the proximal interphalangeal joint, on finger surface (included periungueal ulcers),- of ischemic origin according to the physician,- not over subcutaneous calcifications or bone relief,- active DU- refractory after 10±2 weeks of standard of care (that is either still active or new occurrence despite standard of care)Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2019-003906-28-FRCHU de Toulouse32
Completed
Not Applicable
Periurethral injection of autologous adipose-derived stem cells from liposuction for the treatment of stress urinary incontinencestress urinary incontinenceJPRN-UMIN000006116Department of Urology, Nagoya University Graduate School of Medicine30
Not yet recruiting
Not Applicable
Intra-articular injection of adipose-derived stromal vascular fraction in osteoarthritis of the temporomandibular jointNL-OMON24620MCG40
Withdrawn
Not Applicable
Intra-articular injection of adipose-derived stromal vascular fraction in osteoarthritis of the temporomandibular jointJaw complaintsOsteoarthritis10023213NL-OMON51137niversitair Medisch Centrum Groningen40
Not yet recruiting
Phase 1
Azoospermia Treatment with Mesenchymal Stem Cellon-obstructive Azoospermia.IRCT20190519043634N1ational Center of Science and Technology Evaluation10